Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00309504
First received: March 31, 2006
Last updated: March 30, 2012
Last verified: March 2012

March 31, 2006
March 30, 2012
March 2006
February 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00309504 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy
Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

The purpose of this study is to find ways to improve the appearance of tumours or markers that indicate the presence of tumours in Magnetic Resonance Imaging (MRI). Although based on the same technology, there are many ways to obtain images using MRI. The type of image that will be produced by the scanner depends on the instructions sent to the machine. These instructions tell different components of the machine when to turn on and off and all together are called a pulse sequence. These pulse sequences can get quite lengthy and intricate and small changes in them can produce considerable changes in the resulting image. the aim of this protocol is to alter existing pulse sequences to improve image appearance. This protocol will involve only healthy volunteers.

Not Provided
Observational
Observational Model: Case-Only
Not Provided
Not Provided
Non-Probability Sample

Local Healthy volunteers

Healthy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy adult

Exclusion Criteria:

  • subject under 18 years of age
  • subject pregnant, or may be pregnant
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00309504
22307
Yes
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Gino B. Fallone, PhD, FCCPH, DABR AHS Cancer Control Alberta
AHS Cancer Control Alberta
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP